Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the current HIV drug market will expand with the help of recently launched products from Bristol-Myers Squibb and Gilead. Bristol-Myers Squibb's Reyataz is the first once-daily protease inhibitor that also has a favorable lipid side-effect profile. Gilead's Truvada is a highly potent, well-tolerated, convenient, once-daily fixed-dose combination of two non-nucleoside reverse transcriptase inhibitors. Increased uptake of both products will drive overall sales growth in the near term. In the longer term, classes with novel mechanisms of action will expand the market.
According to the new Pharmacor study entitled HIV: Analysis of Drug Development and Emerging Therapeutics, the new additions from conventional antiretroviral (ARV) drug classes include Boehringer Ingelheim's tipranavir and Johnson & Johnson's TMC-114 and TMC-125. Additionally, emerging classes in advanced stages of development, including the CCR5 antagonists and the integrase inhibitors, appear highly promising and may have a major clinical and commercial impact.
"Growing resistance to current ARV products will drive the uptake of new products within the conventional ARV classes (e.g., protease inhibitors, non- nucleoside reverse transcriptase inhibitors, nucleoside/nucleotide reverse transcriptase inhibitors) as well as the emerging classes," said John Lebbos, M.D., therapeutic area director at Decision Resources. "The novel classes have the potential to address key unmet needs in HIV treatment. These products will be priced at a premium to current ARVs and will expand the overall market."
About HIV: Analysis of Drug Development and Emerging Therapeutics
The new HIV: Analysis of Drug Development and Emerging Therapeutics study offers readers:
* A broad look at the HIV pipeline with a comprehensive discussion of emerging classes and earlier-stage products. * The advantages, disadvantages, market positioning, and risks of emerging classes of HIV drugs. * Competitive assessment of how emerging products will impact current market leaders. * Fifteen-year epidemiology and sales projections. * Discussion of regulatory requirements for approval as well as an overview of clinical programs of recently approved products. * Detailed analysis of unmet needs by antiretroviral class, as well as characteristics required for an emerging product within conventional and novel classes. * Analysis of strategies for success from a drug development and portfolio planning perspective: What corporate strategies have worked in the past? What will work in the future given the current trends in HIV? In what emerging classes should companies be investing to be future leaders or to be attractive in-licensing/acquisition targets? About Pharmacor from Decision Resources
Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.
About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563
Web site: http://www.decisionresources.com/